Communication
ChemComm
Conflicts of interest
There are no conflicts to declare.
Notes and references
1 C. Plummer, A. Michael, G. Shaikh, M. Stewart, L. Buckley, T. Miles,
A. Ograbek and T. McCormack, Br. J. Cancer, 2019, 121, 109–116.
2 M. D. Hellmann, B. T. Li, J. E. Chaft and M. G. Kris, Ann. Oncol.,
2016, 27, 1829–1835.
3 G. Housman, S. Byler, S. Heerboth, K. Lapinska, M. Longacre,
N. Snyder and S. Sarkar, Cancers, 2014, 6, 1769–1792.
4 R. Injac, M. Perse, M. Cerne, N. Potocnik, N. Radic, B. Govedarica,
A. Djordjevic, A. Cerar and B. Strukelj, Biomaterials, 2009, 30, 1184–1196.
5 H. A. Hirsch, D. Iliopoulos, P. N. Tsichlis and K. Struhl, Cancer Res.,
2009, 69, 7507–7511.
6 O. C. Farokhzad and R. Langer, ACS Nano, 2009, 3, 16–20.
7 B. S. Pattni, V. V. Chupin and V. P. Torchilin, Chem. Rev., 2015, 115,
10938–10966.
8 K. Yang, L. Feng and Z. Liu, Adv. Drug Delivery Rev., 2016, 105, 228–241.
9 R. Khatik, Z. Wang, F. Li, D. Zhi, S. Kiran, P. Dwivedi, R. X. Xu,
G. Liang, B. Qiu and Q. Yang, Nanomedicine, 2019, 15, 264–273.
10 J. Vandooren, G. Opdenakker, P. M. Loadman and D. R. Edwards,
Adv. Drug Delivery Rev., 2016, 97, 144–155.
Fig. 4 Time course of the in vivo study for antitumor effects of intrave-
nously injected PBS, free Dox, FF–Dox and FA–FF–Dox on HeLa tumors
bearing nude mice (n = 6 for each group). (A) Change in the tumor volume
during the study. (B) Body weight changes in the nude mice during the
treatment. (*, ‡, p o 0.01 FA–FF–Dox vs. PBS and Dox and #, p o 0.05
FA–FF–Dox vs. FF–Dox).
major changes in the heart tissue. However, necrosis at the
tumor tissue was clearly evident in the treated group compared 11 S. Eskandari, T. Guerin, I. Toth and R. J. Stephenson, Adv. Drug
Delivery Rev., 2017, 110–111, 169–187.
12 H. Hosseinkhani, P.-D. Hong and D.-S. Yu, Chem. Rev., 2013, 113,
to that in the control which was much significant in the mice
treated with FA–FF–Dox. The cells of tumor sections of the
4837–4861.
control group were densely populated with a regular shape 13 J. A. Crapster, I. A. Guzei and H. E. Blackwell, Angew. Chem., Int. Ed.,
2013, 52, 5079–5084.
14 M. Caruso, E. Placidi, E. Gatto, C. Mazzuca, L. Stella, G. Bocchinfuso,
whereas the cells of tumor sections of the other groups were
shrunk and signs of apoptosis were visible being maximum for
A. Palleschi, F. Formaggio, C. Toniolo and M. Venanzi, J. Phys.
the FA–FF–Dox group.
Chem. B, 2013, 117, 5448–5459.
15 Y.-R. Yoon, Y.-b. Lim, E. Lee and M. Lee, Chem. Commun., 2008,
1892–1894.
16 S. Li, A. K. Mehta, A. N. Sidorov, T. M. Orlando, Z. Jiang, N. R. Anthony
and D. G. Lynn, J. Am. Chem. Soc., 2016, 138, 3579–3586.
17 V. A. Kumar, N. L. Taylor, S. Shi, B. K. Wang, A. A. Jalan, M. K. Kang,
N. C. Wickremasinghe and J. D. Hartgerink, ACS Nano, 2015, 9, 860–868.
In summary, we report the development of functionalized
and non-functionalized self-assemblies of dipeptides for pH
sensitive and targeted delivery of Dox. To the best of our knowl-
edge, we are the first to report pH sensitive FA–FF-NPs. These
nanoparticles demonstrated great potential in FR mediated
targeted delivery and intracellular pH sensitive release of drugs.
Such an FR mediated drug delivery strategy would be able to
facilitate the endocytosis of functionalized nanoparticles into
´
18 P. Boisguerin, S. Deshayes, M. J. Gait, L. O’Donovan, C. Godfrey,
C. A. Betts, M. J. A. Wood and B. Lebleu, Adv. Drug Delivery Rev.,
2015, 87, 52–67.
19 A. Gabizon, A. T. Horowitz, D. Goren, D. Tzemach, H. Shmeeda and
S. Zalipsky, Clin. Cancer Res., 2003, 9, 6551–6559.
´
tumor cells, enable drug release at the acidic pH due to the 20 M. Fernandez, F. Javaid and V. Chudasama, Chem. Sci., 2018, 9, 790–810.
21 P. Xu, H. Zuo, B. Chen, R. Wang, A. Ahmed, Y. Hu and J. Ouyang, Sci.
Rep., 2017, 7, 42632.
22 P. Gou, W. Liu, W. Mao, J. Tang, Y. Shen and M. Sui, J. Mater. Chem.
protonation of amines and hydrolysis of Schiff base, increase
intracellular drug accumulation, and consequently enhance the
cytotoxicity to the tumor cells. Fluorescence imaging at 24 h after
intravenous administration of FA–FF-NPs revealed increased
uptake and retention of nanoparticles in tumor cells. Hence,
B, 2013, 1, 284–292.
23 A. Maillet, K. Tan, X. Chai, S. N. Sadananda, A. Mehta, J. Ooi,
M. R. Hayden, M. A. Pouladi, S. Ghosh, W. Shim and L. R. Brunham,
Sci. Rep., 2016, 6, 25333.
we conclude that self-assembled peptides could be employed for 24 R. F. Silva, D. R. Arau´jo, E. R. Silva, R. A. Ando and W. A. Alves,
Langmuir, 2013, 29, 10205–10212.
targeted delivery to tumors with high payload of the drug to
´
25 A. B. Seabra and N. Duran, Peptides, 2013, 39, 47–54.
boost the therapeutic outcome of chemotherapeutics.
The Collaborative Innovation Center of Suzhou Nano Science
and Technology (BK20161139) and the Ministry of Science and
Technology of China (2016YFA0400904) are acknowledged. The
author SK acknowledges the CAS-TWAS president fellowship
(2016-169). PD and MD acknowledge the State Administration
of Foreign Experts Affairs grant numbers WQ20180103 and
WQ20180102, respectively.
26 W. Tang, Z. Zhao, Y. Chong, C. Wu, Q. Liu, J. Yang, R. Zhou, Z.-X. Lian
and G. Liang, ACS Nano, 2018, 12, 9966–9973.
27 W. Tang, J. Yang, Y. Yuan, Z. Zhao, Z. Lian and G. Liang, Nanoscale,
2017, 9, 6529–6536.
28 S. Kiran, Z. Hai, Z. Ding, L. Wang, Y. Liu, H. Zhang and G. Liang,
Chem. Commun., 2018, 54, 1853–1856.
29 N. Habibi, N. Kamaly, A. Memic and H. Shafiee, Nano Today, 2016,
11, 41–60.
30 P. Zhang, A. G. Cheetham, Y.-A. Lin and H. Cui, ACS Nano, 2013, 7,
5965–5977.
288 | Chem. Commun., 2020, 56, 285--288
This journal is © The Royal Society of Chemistry 2020